IL-22 partial agonist program / Synthekine - LARVOL DELTA

Synthekine Licenses Additional Cytokine Programs (Businesswire) - “Synthekine…announced a new agreement with Stanford University to license cytokine partial agonist programs for IL-10, IL-12 and IL-22. These programs augment a growing pipeline of selective cytokine partial agonists at Synthekine that is maturing toward clinical development…Synthekine plans to leverage discoveries in IL-12, recently published in the journal Cell, to develop potential treatments for cancer…”

Licensing / partnership • Oncology